Predicting Malignancy Risk of Screen-Detected Lung Nodules-Mean Diameter or Volume.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
02 2019
Historique:
received: 30 07 2018
revised: 07 10 2018
accepted: 09 10 2018
pubmed: 28 10 2018
medline: 9 4 2020
entrez: 28 10 2018
Statut: ppublish

Résumé

In lung cancer screening practice low-dose computed tomography, diameter, and volumetric measurement have been used in the management of screen-detected lung nodules. The aim of this study was to compare the performance of nodule malignancy risk prediction tools using diameter or volume and between computer-aided detection (CAD) and radiologist measurements. Multivariable logistic regression models were prepared by using data from two multicenter lung cancer screening trials. For model development and validation, baseline low-dose computed tomography scans from the Pan-Canadian Early Detection of Lung Cancer Study and a subset of National Lung Screening Trial (NLST) scans with lung nodules 3 mm or more in mean diameter were analyzed by using the CIRRUS Lung Screening Workstation (Radboud University Medical Center, Nijmegen, the Netherlands). In the NLST sample, nodules with cancer had been matched on the basis of size to nodules without cancer. Both CAD-based mean diameter and volume models showed excellent discrimination and calibration, with similar areas under the receiver operating characteristic curves of 0.947. The two CAD models had predictive performance similar to that of the radiologist-based model. In the NLST validation data, the CAD mean diameter and volume models also demonstrated excellent discrimination: areas under the curve of 0.810 and 0.821, respectively. These performance statistics are similar to those of the Pan-Canadian Early Detection of Lung Cancer Study malignancy probability model with use of these data and radiologist-measured maximum diameter. Either CAD-based nodule diameter or volume can be used to assist in predicting a nodule's malignancy risk.

Identifiants

pubmed: 30368011
pii: S1556-0864(18)33187-3
doi: 10.1016/j.jtho.2018.10.006
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-211

Informations de copyright

Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Auteurs

Martin Tammemagi (M)

Department of Health Sciences, Brock University, St. Catharine's, Ontario, Canada.

Alex J Ritchie (AJ)

Royal Brisbane and Women's Hospital, Brisbane, Australia.

Sukhinder Atkar-Khattra (S)

British Columbia Cancer, Vancouver, British Columbia, Canada.

Brendan Dougherty (B)

Flinders Medical Centre, Adelaide, Australia.

Calvin Sanghera (C)

British Columbia Cancer, Vancouver, British Columbia, Canada.

John R Mayo (JR)

Department of Radiology, Vancouver Coastal Health, Vancouver, British Columbia, Canada.

Ren Yuan (R)

British Columbia Cancer, Vancouver, British Columbia, Canada.

Daria Manos (D)

Dalhousie University, Halifax, Nova Scotia, Canada.

Annette M McWilliams (AM)

Fiona Stanley Hospital and Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

Heidi Schmidt (H)

University Health Network and Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Michel Gingras (M)

University Institute of Cardiology and Pneumology of Quebec, Quebec, Canada.

Sergio Pasian (S)

University Institute of Cardiology and Pneumology of Quebec, Quebec, Canada.

Lori Stewart (L)

Department of Diagnostic Imaging, Henderson Hospital, Hamilton, Ontario, Canada.

Scott Tsai (S)

Department of Diagnostic Imaging, Henderson Hospital, Hamilton, Ontario, Canada.

Jean M Seely (JM)

Ottawa Hospital Research Institute and the University of Ottawa, Ottawa, Ontario, Canada.

Paul Burrowes (P)

University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada.

Rick Bhatia (R)

Memorial University, St. John's, Newfoundland, Canada.

Ehsan A Haider (EA)

Department of Diagnostic Imaging, Henderson Hospital, Hamilton, Ontario, Canada.

Colm Boylan (C)

Department of Diagnostic Imaging, Henderson Hospital, Hamilton, Ontario, Canada.

Colin Jacobs (C)

Radboud University Medical Center, Nijmegen, The Netherlands.

Bram van Ginneken (B)

Radboud University Medical Center, Nijmegen, The Netherlands.

Ming-Sound Tsao (MS)

University Health Network and Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Stephen Lam (S)

British Columbia Cancer, Vancouver, British Columbia, Canada. Electronic address: slam@bccancer.bc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH